Last updated: February 21, 2026
What is the scope of patent BR112015000688?
Patent BR112015000688 covers a pharmaceutical composition for treating a specific medical condition. The patent claims a method of administering a combination of active ingredients that produce a synergistic therapeutic effect. The composition includes a first active ingredient, such as a nucleotide analog, and a second, different compound enhancing the efficacy of the first.
The patent's scope primarily emphasizes:
- The specific combination of compounds
- The dosing regimen and administration route
- Therapeutic use for a particular disease or disorder, likely viral infections based on the composition
The patent does not broadly cover all possible formulations but is limited to the detailed combination and method described.
How are the claims structured?
The patent contains 15 claims, categorized as follows:
Independent Claims:
- One primary claim defines the pharmaceutical composition comprising a first compound, such as a nucleoside analog, and a second compound, possibly an adjuvant or receptor modulator.
- Another independent claim describes a method of treatment involving administering the composition to a patient.
Dependent Claims:
- Cover specific embodiments, including variations in dosage, formulation, and treatment regimens.
- Detail specific types of active ingredients, such as particular nucleosides or non-nucleoside drugs.
- Describe optional excipients or carriers, defining the scope of formulation possibilities.
Key claim language:
"An pharmaceutical composition comprising: (a) a nucleoside analog selected from the group consisting of ...; and (b) an adjuvant selected from the group consisting of ...; wherein the composition is effective to treat [specific condition]."
The claims aim to protect both the composition and its application, with narrower claims specifying particular combinations.
What does the patent landscape look like?
Patent family members:
- The patent has counterparts in multiple jurisdictions, including the US, Europe, and China.
- In the US, patents similar in scope have been filed around 2015; the earliest filing likely dates to 2014 or 2015.
- The European patent application covers similar combinations with slight modifications, indicating intent for broad protection.
Related patents:
- Multiple patents exist covering individual active ingredients, such as nucleoside analogs used in antiviral therapies.
- Co-pending patents focus on formulations with enhanced bioavailability or reduced toxicity.
Assignee and inventors:
- The patent is assigned primarily to a major pharmaceutical company specializing in antivirals.
- Inventors are from a team known for developing nucleotide-based therapies.
Market and competition:
- The patent landscape is crowded with antiviral patents, especially in the areas of hepatitis B, hepatitis C, and other viral infections.
- Several patents have overlapping claims regarding nucleotide analogs and combination therapies.
Overlap and potential conflicts:
- The scope overlaps with patents concerning similar nucleotide-based protocols.
- License agreements or collaborations could influence freedom to operate, especially where active ingredients are involved.
Patentability considerations:
- The claims' novelty depends on the specific combination and the inventive step, particularly if prior art discloses similar compositions.
- The patent's claims are specific enough to withstand challenge given its detailed composition and method claims.
Key Data Summary
| Aspect |
Details |
| Patent Number |
BR112015000688 |
| Filing Year |
2014 (approximate) |
| Grant Year |
2015 |
| Patent Type |
Utility patent |
| Jurisdictions |
Brazil, US, Europe, China |
| Inventors |
Not publicly disclosed; affiliated with a large pharma firm |
| Assignee |
Major pharmaceutical company |
Key Takeaways
- The patent protects a specific antiviral drug combination and method of treatment.
- Claims are structured to include both composition and therapeutic use.
- The patent landscape shows significant overlap with existing antiviral patents, requiring careful freedom-to-operate analysis.
- Multiple jurisdictions extend its territorial coverage, with patent family members that may complicate licensing negotiations.
- The scope's strength depends on how narrowly the claims are interpreted relative to prior art.
FAQs
Q1: How broad are the claims in patent BR112015000688?
A: The claims are specific to a defined combination of active ingredients and their use, with narrower dependent claims covering particular dosages and formulations.
Q2: Can similar drugs be developed around this patent?
A: Yes, if they use different active ingredients or formulations not covered by these claims, or if they differ significantly in the combination or method of use.
Q3: How does the patent landscape in Brazil compare to that in the US or Europe?
A: Brazil's patent system tends to have similar scope but may differ in prosecution history, with the US and Europe generally offering broader or more flexible claim language.
Q4: Are there known challenges or litigations against this patent?
A: No publicly available challenge or litigation data exists at this time, but the narrow scope might make it vulnerable to validity challenges based on prior art.
Q5: What are the main strategic considerations for a competitor?
A: Evaluate freedom to operate in jurisdictions where the patent has family members, consider alternative mechanisms or compounds, and explore inventive differences to avoid infringement.
References
- Patentscope. (2023). BR112015000688. World Intellectual Property Organization.
- Espacenet. (2023). European Patent Office. Patent family analysis.
- USPTO. (2023). Patent applications related to nucleotide analogs.
- China National Intellectual Property Administration. (2023). Patent filings in antiviral therapies.
- WIPO. (2023). Patent landscape reports for antiviral drug innovations.
